<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03596957</url>
  </required_header>
  <id_info>
    <org_study_id>PoCKET</org_study_id>
    <nct_id>NCT03596957</nct_id>
  </id_info>
  <brief_title>Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease</brief_title>
  <acronym>PoCKET</acronym>
  <official_title>Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lisbet Brandi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordsjaellands Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Investigator initiated controlled multi-centre trial in a Prospective, Randomised, Open,
      Blinded Endpoint (PROBE) design.

      Patients will be randomised in a 1:1 ratio either to treatment with tolvaptan for six weeks
      followed by six weeks observation without trial medication or no tolvaptan treatment, but
      following the same visit and investigation plan as the subjects taking tolvaptan.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic kidney
      disease and the fourth leading cause of end-stage renal disease in adults Worldwide.

      The tolvaptan tablet has been approved by EMA (European Medicines Agency) with the indication
      of slowing the progression of cysts development and renal insufficiency in adults with ADPKD.
      It is the newest and only possible treatment for this patient group and could be initiated in
      patients with evidence for rapidly progressive disease Development.

      There is however in Denmark and other countries both scientific and financial reluctance to
      initiate this expensive treatment for several reasons e.g. selection of patients who might
      benefit, effect on progression of kidney disease, side effects and tolerability.

      Before deciding on implementation in Denmark, more knowledge is needed. The results of the
      PoCKET trial will contribute with guidance on this decision.

      Foremost the trial is designed to address not only the change in kidney volume, but the
      change in kidney function, which is what matters to the patients and their prognosis in terms
      of postponing time to end stage renal disease. Furthermore, important data on side effects
      and tolerability will be generated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomised in a 1:1 ration either to treatment with tolvaptan for six weeks followed by six weeks observation without trial medicaion or to the Control group receiving no tolvaptan treatment for 12 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The endpoint blinding will be assured since all the MRI scans will be forwarded to the Comparative Medicine Laboratory in Aarhus for evaluation</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in total Kidney Volume (tKV) measured by MRI scanning</measure>
    <time_frame>Between baseline and six weeks and between six and 12 weeks</time_frame>
    <description>The change in the total Kidney Volume after six and 12 weeks participation in the trial</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in GFR</measure>
    <time_frame>Between baseline and six weeks and between baseline and 12 weeks</time_frame>
    <description>The changes in GFR measured by Cr-EDTA clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in relevant genetic and non-genetic biomarkers associated with CKD and ESRD</measure>
    <time_frame>Between baseline and six weeks and between baseline and 12 weeks</time_frame>
    <description>Prediction of change in progression of the disease over time in the genes PKD1, PKD2, PKHD1 and HNF1B. The following biomarkers will be determined: NGAL, UMOD, MCP-1, KIM-1, cystatin-C and copeptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life</measure>
    <time_frame>Between baseline and six weeks and between baseline and 12 weeks</time_frame>
    <description>Questionnaire SF36 Health Survey - with 36 questions to subject's health and wellbeing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject estimation of own health</measure>
    <time_frame>Between baseline and six weeks and between baseline and 12 weeks</time_frame>
    <description>Estimated by a Visual Analogue Scale from 0 (worth wellbeing) to 100 (best wellbeing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ASAT and ALAT</measure>
    <time_frame>Between baseline and six weeks and between baseline and 12 weeks</time_frame>
    <description>Changes estimated from laboratory results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Between baseline and six weeks and between baseline and 12 weeks</time_frame>
    <description>Evaluation of Adverse Events including severity, causality, outcome and seriousness assessments</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney</condition>
  <arm_group>
    <arm_group_label>Tolvaptan group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with tolvaptan for six weeks followed by six weeks observation without trial medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No tolvaptan treatment but following the same visit and investigation plan as the subjects in the tolvaptan group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>At baseline the tolvaptan dosing will start with daily morning and afternoon doses of 45 mg and 15 mg respectively, with weekly increases to 60 mg and 30 mg and then to 90 mg and 30 mg according to subject tolerability</description>
    <arm_group_label>Tolvaptan group</arm_group_label>
    <other_name>Jinarc</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients between 18 and 65 years

          -  Diagnosis of typical ADPKD

          -  tKV above or equal to 750 ml by MRI scanning

          -  Estimated GFR (e-GFR) by CKD-EPI formula of above or equal to 45 mL/min/1.73 m2

        Exclusion Criteria:

          -  Kidney transplant recipient

          -  Known liver disease except for liver cysts relating to ADPKD

          -  ASAT and ALAT above upper normal level

          -  Current treatment with thiazide and thiazide-line diuretics, mineral corticoid
             receptor antagonists, amiloride or loop diuretics

          -  Evidence of urinary tract obstruction

          -  Current treatment with CYP3A4 inhibitors

          -  Active malignant disease

          -  Current or previous treatment with tolvaptan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisbet Brandi, MD DMSc MHM</last_name>
    <role>Principal Investigator</role>
    <affiliation>KNEA, Nordsjaellands Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisbet Brandi, MD DMSc MHM</last_name>
    <phone>+45 48295993</phone>
    <email>lisbet.brandi@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinical Project Manager</last_name>
    <phone>+45 48294714</phone>
    <email>charlotte.bjernved.nielsen@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital - Site 43</name>
      <address>
        <city>Skejby</city>
        <state>Aarhus N</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Birn, MD</last_name>
      <phone>+45 6171 7870</phone>
      <email>hb@biomed.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Karin Hansen</last_name>
      <phone>+45 4046 0831</phone>
      <email>Karin.hansen@skejby.rm.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital - Site 45</name>
      <address>
        <city>Odense</city>
        <state>Odense C</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Helle Thiesson, MD</last_name>
      <phone>+45 6541 1642</phone>
      <email>helle.thiesson@rsyd.dk</email>
    </contact>
    <contact_backup>
      <last_name>Kristian Bergholt Buhl, MD</last_name>
      <phone>+456541 1642</phone>
      <email>kristian.bergholt.buhl@rsyd.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet - Site 42</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Feldt-Rasmussen, MD</last_name>
      <phone>+45 3545 2135</phone>
      <email>Bo.Feldt-Rasmussen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Tobias Bomholt, MD</last_name>
      <phone>+45 35451838</phone>
      <email>tobias.bomholt@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ditte Hansen, MD</last_name>
      <phone>+45 3868 2056</phone>
      <email>ditte.hansen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Marie Moeller, MD</last_name>
      <phone>+45 6169 5364</phone>
      <email>marie.moeller@regioh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Nordsjaellands Hospital - Site 41</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisbet Brandi, MD</last_name>
      <phone>+45 48295993</phone>
      <email>lisbet.brandi@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Charlotte Bjernved Nielsen</last_name>
      <phone>+45 49294714</phone>
      <email>charlotte.bjernved.nielsen@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Sjællands University Hospital Roskilde</name>
      <address>
        <city>Roskilde</city>
        <zip>4000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bjarne Ørskov, MD</last_name>
      <phone>+45 2966 2426</phone>
      <email>bjaoe@regionsjalelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>February 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2018</study_first_posted>
  <last_update_submitted>November 22, 2018</last_update_submitted>
  <last_update_submitted_qc>November 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Nordsjaellands Hospital</investigator_affiliation>
    <investigator_full_name>Lisbet Brandi</investigator_full_name>
    <investigator_title>Head of Department for Endrocrinology and Nephrology, MD, DMSc, MHM</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

